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Abstract
Background: Treatment of non-small cell lung cancer with novel targeted therapies is a major unmet clinical
need. Alternative splicing is a mechanism which generates diverse protein products and is of functional relevance
in cancer.
Results: In this study, a genome-wide analysis of the alteration of splicing patterns between lung cancer and
normal lung tissue was performed. We generated an exon array data set derived from matched pairs of lung
cancer and normal lung tissue including both the adenocarcinoma and the squamous cell carcinoma subtypes. An
enhanced workflow was developed to reliably detect differential splicing in an exon array data set. In total, 330
genes were found to be differentially spliced in non-small cell lung cancer compared to normal lung tissue.
Microarray findings were validated with independent laboratory methods for CLSTN1, FN1, KIAA1217, MYO18A,
NCOR2, NUMB, SLK, SYNE2, TPM1, (in total, 10 events) and ADD3, which was analysed in depth. We achieved a high
validation rate of 69%. Evidence was found that the activity of FOX2, the splicing factor shown to cause cancer-
specific splicing patterns in breast and ovarian cancer, is not altered at the transcript level in several cancer types
including lung cancer.
Conclusions: This study demonstrates how alternatively spliced genes can reliably be identified in a cancer data
set. Our findings underline that key processes of cancer progression in NSCLC are affected by alternative splicing,
which can be exploited in the search for novel targeted therapies.
Background
Lung cancer accounts for a quarter of all cancer mortal-
ities in the U.S. [1]. Non-small-cell lung cancer
(NSCLC) is a histologically defined sub-group that
represents 75 to 80% of all lung cancer cases. NSCLC
can be subdivided into adenocarcinoma (AdCa), squa-
mous cell carcinoma (SCC), and large cell lung cancer
(LCLC). The high mortality rate of lung cancer can be
attributed to late diagnosis and thus an already metasta-
sised and aggressive tumour. Platinum-based che-
motherapy in combination with taxanes, camptothecins,
or vinca alkaloids, is the first-line treatment of choice
for patients with advanced NSCLC [2]. Yet, survival
time is short and the five-year survival rate has only
risen slightly since 1987 [1]. New therapies address
molecular targets that are involved in tumour progres-
sion or angiogenesis (e.g. EGFR, VEGF-R) [3]. These
involve small molecule drugs directed against mutated
EGFR (e.g. gefitinib, erlotinib), as well as monoclonal
antibodies directed against EGFR (cetuximab) and
against VEGF (bevacizumab). These targeted therapeu-
tics have provided some clinical benefit but also under-
lined that the molecular target needs to be accessible in
the tumour type under treatment. That is, administering
the drug will provide benefit to patients only for specific
sub-types of the tumour where the target is relevant,
thereby introducing the concept of an individualised
therapy. Novel drugs for a targeted therapy that con-
sider the sub-type specific tumour biology are urgently
needed as treatment of NSCLC - a major unmet clinical
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any medium, provided the original work is properly cited.need. In order to better understand molecular character-
istics of NSCLC and derive novel molecular targets, stu-
dies have investigated gene expression in clinical
samples [4] or in novel xenograft models derived from
NSCLC specimens [5], gene expression under com-
pound treatment (e.g. Sagopilone [6]), DNA copy-
number variation [7], and epigenetic changes [8] in
NSCLC in an unbiased approach. Yet, the changes caused
by alternative splicing are relatively unexplored in NSCLC.
Alternative splicing (AS) describes the process by
which pre-mRNA is spliced in different ways thus giving
rise to distinct mature mRNA transcripts [9]. AS events
can be characterised as inclusion or skipping of a com-
plete exon (cassette exon, CE), prolongation or shorten-
ing of an exon (alternative 5’-o r3 ’-splice site), retention
of an intron (IR), inclusion of only one exon from an
array of two or more exons (mutually exclusive exons,
MX), and alternative poly-A site [10]. Also alternative
start of transcription can lead to different exon-exon
junctions; however, this mechanism is not an AS event
and its regulation need not be at the level of splicing. It
has become evident that more than 73% of all human
genes are alternatively spliced [11,12]. AS plays a major
role in gene regulation, both in normal tissues as well as
in disease. In cancer, AS has an impact on cellular pro-
cesses related to tumour progression, including inhibi-
tion of apoptosis, tumour invasion, metastasis, and
angiogenesis [13]. Changes of the AS pattern of a gene
can be triggered by differential expression of splicing
factors or by changes up-stream of the splicing machin-
ery. One example is SRPK1, a kinase that is over-
expressed in breast, colon, and pancreas carcinoma [14].
SRPK1 phosphorylates the splicing factor SF2/ASF,
thereby mediating its import into the nucleus and
recruitment to nuclear speckles [15]. This process
affects the AS of multiple target genes (e.g. BIN1, S6K1,
MNK2) which contributes to tumour progression [16].
Based on the analysis of ESTs from normal and cancer-
ous tissues it was suggested that alterations affecting the
splicing machinery and its regulation are a further hall-
mark of cancer progression [17]. Both the identification
of RNA binding proteins affecting the AS pattern as
well as their target sequences are active fields of
research [18,19].
Most studies of AS in cancer focused on the analysis
of individual genes. Several genes are well-known for AS
and derived alternative proteins have different function-
alities in tumour compared to normal tissue. One mem-
b e ro ft h eB c l - 2f a m i l yi sB c l - X( BCL2L1), whose short
transcript variant Bcl-XS promotes apoptosis. AS results
in a longer exon in the transcript variant Bcl-XL in can-
cer cells. In contrast to the short transcript variant, this
isoform has an anti-apoptotic function [20]. CD44 is
another example of a gene that is affected by AS. Ten
variant exons in this gene generate multiple transcript
variants. In most tissues, the short isoform CD44S lack-
ing all variant exons is expressed. Longer transcript var-
iants containing one or many variant exons were found
in specific cell types as well as in cancer cells. It was
shown that the transcript variants of CD44 are involved
in angiogenesis and metastasis [21,22]. AS can also yield
new epitopes in tumour cell surface proteins or in pro-
teins of the extracellular matrix of tumour cells that can
be exploited for therapy via targeting by an immunocon-
jugate. Using such an approach, CD44-v6 was targeted
by the immunoconjugate bivatuzumab mertansine [23].
The Fibronectin (FN1) gene codes for an extracellular
matrix protein that contains three cassette exons,
among them the extradomain B exon (EDB) [24]. An
antibody fragment targeting the onco-foetal antigen
FN1-EDB (L19-SIP) is currently in pre-clinical develop-
ment [25]. All these examples demonstrate that AS is a
highly interesting field: on the one hand, elucidating
induced changes along the hallmarks of cancer [26] and,
on the other hand, in the search for new drug targets,
both for small molecule as well as for antibody-mediated
approaches. Nevertheless, it remains a relatively unex-
plored area. Until recently, methods for a global analysis
of AS were challenging and required a great deal of
effort.
As a new technology that allow an unbiased analysis
of AS, splice variant sensitive microarrays became com-
mercially available in 2005. In this study, we utilise the
oligonucleotide microarray Human Exon 1.0 ST Array
(Affymetrix, Santa Clara, CA, USA). This array contains
6.5 million probes targeting known and predicted exons
of the human transcriptome [27]. Probe sequences were
designed in such a way that up to four probes compose
a probe set that maps to one exon of a gene. Probe
intensities can be summarised on the gene level which
provides information about expression of the whole
gene. In addition, the exon array technology allows sum-
marisation per probe set which provides exon expres-
sion values. One can determine the relative inclusion or
skipping rate of an exon between two or more sample
groups (differential splicing) using both metrics together.
Although alternative start of transcription is not an AS
event, the exon array technology can also detect differ-
ences in the usage of transcription start sites. In the fol-
lowing, we also consider this kind of mechanism when
speaking of differential splicing.
In previous studies (review [28]), the exon array tech-
nology was used to detect differences in AS patterns
between healthy human tissues [29], between human
populations [30], under hypoxia conditions [31], and in
disease tissues. Differential splicing was analysed in sev-
eral types of cancer, among them colon, breast, prostate,
bladder, and head and neck cancers [27,32,33]. Clinical
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dies: Xi et al. analysed a data set of matched pairs of
AdCa [34]. They found evidence for differential splicing
in 2369 genes and further analysed a subset of 729
genes that are cancer-related according to pathway
annotations. Of 11 genes selected for a validation using
independent laboratory methods, differential splicing
was confirmed in six genes (CEACAM1, ERG, RASIP1,
VEGFC, CDKN2A, CDH3). Lin et al. analysed differen-
tial splicing in a large data set consisting of samples of
AdCa and SCC of NSCLC besides colon and breast can-
cer [35]. This data set does not contain samples of
healthy tissue for comparison.
Data analysis of exon arrays remains a challenging
task despite several different approaches described
recently [27,33-35]. In the workflow proposed by Affy-
metrix, exon level expression values are normalised to
gene level expression values to calculate the splicing
index (SI) [36]. Differentially spliced genes are identified
using both the magnitude of change (SI) as well as sig-
nificance, e.g. p value obtained from a Student’s t-test. It
became evident that the standard workflow leads to a
high false positive rate which especially affects noisy
data sets such as cancer data sets with high intrinsic
variability due to inter-patient heterogeneity [27]. Three
sources of artefacts are thought to be the major cause of
false positives: (1) Probe intensities at the background
noise, (2) cross-hybridising probes, and (3) imprecise
calculation of the SI.
(1) Probes corresponding to exons that are not
expressed in a particular sample group measure the
background noise and thus will not be informative. Still,
their expression value does not follow the overall gene
expression level thus leading to high SI values and false
positive results. It is generally accepted that it is desir-
able to remove this kind of probes before conducting
the analysis [37]. Here, the difficulty resides in identify-
ing probes that are in fact detecting signals above the
background noise. Algorithms initially employed like
DABG were based on the GC-content of the probes
[29,38]. Recent advances in this field incorporate a
statistical model based on probe sequences (MAT
algorithm [39]) or a thermodynamic model of oligonu-
cleotide hybridisation (MSNS algorithm [40]).
(2) Cross-hybridising probes are probes that bind
other sequences besides the intended exon. This can
lead to a constantly high expression value that does not
follow the gene-level expression value. Again, this will
lead to a high SI and to false positives. To date, this
issue has been addressed with either of two approaches:
mapping of probes sequences to the transcriptome and
flagging potential candidates probes that have multiple
hits [41] or filtering out probes with a constantly high
expression value [36].
(3) The third kind of artefact can be attributed to dif-
ficulties in measuring the SI. As mentioned by Affyme-
trix, determination of the correct gene level
summarisation value can be cumbersome [36]. It can be
estimated in general more reliably for a gene with many
constitutive exons and preferably only a small number
of exons affected by AS. A number of improvements
were published trying to identify constitutive exons
[42-44]. As another approach, Shah and Pallas used a
correlation-based approach in favour of calculating the
SI [45]. Recently, Möller-Levet et al. introduced the new
metric VFC which is a weighted fold-change based on
probe set reliability, i.e. detection above background
score [33].
In addition to the identification of artefacts as men-
tioned above, a method of analysis needs to consider the
relationship between exons and genes and also annota-
tions of known transcript variants. Apparently, probe set
definitions and annotations provided by Affymetrix were
used in many studies. Affymetrix continuously updates
the annotation files, i.e. the assignment of probe sets to
the latest set of genes and mRNA sequences. Yet other
information is not updated, such as the assignment of
probes to probe sets (chip definition), the assignment of
probe sets to a putative gene locus (transcript cluster),
and the reliability assignment of a probe set (core set,
extended set, full set). As this information is not static,
an analytical method would benefit from an update of
all of these definitions: a probe looking perfect at design
time might in fact map to multiple targets suggesting
exclusion from a probe set. Unfortunately, transcript
and gene annotations may contain some errors; correc-
tions might require remapping between probe sets and
the new gene locus/loci. Predicted exons can get backed
by transcript evidence but might still be omitted from a
study since they have not been moved to the core set.
In part, these issues have been addressed with the data-
base X:Map that provides an up-to-date mapping of
probe sequences to transcripts and genes [46]. In some
studies, X:Map is used either directly or indirectly via
the Bioconductor package Exonmap [47,48]. All of the
analysis workflows discussed above underline that ana-
lysing an exon array data set is a multi-faceted chal-
lenge. In this study, we propose a new workflow that
addresses the above issues. We generated a new chip
definition that represents an updated composition of
probe sets and their assignment to known transcripts
and genes. Furthermore, we use advanced algorithms in
order to remove artefacts and to detect differentially
spliced genes.
With the new workflow we identified genes that exhi-
bit differential splicing in NSCLC compared to normal
adjacent lung tissue (NAT). In order to extend our bio-
logical understanding of AS in cancer, alterations of
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lysed on a genome-wide level. We generated an exon
array data set derived from matched pairs of NSCLC
and NAT including both the AdCa and the SCC sub-
type. Initially, we analysed this data set with a standard
workflow based on the SI (workflow proposed by Affy-
metrix [49]) and the generally accepted analysis of var-
iance (ANOVA; workflow implemented in Partek®
Genomics Suite). Several improvement steps led to our
enhanced workflow. After using the final version, genes
that are known to be differentially spliced in NSCLC
versus NAT can be found ranking highly in the result
list (e.g. FN1). In total, 14 genes of this result list were
selected for validation using independent laboratory
methods. We succeeded in validating 69% of all differen-
tial splicing events. This includes ten events that are
genuine AS events and one alternative transcription
start site event. This proves that our enhanced workflow
can reliably identify genes that are affected by AS even
in a clinical cancer data set that contains different sub-
types of NSCLC and that reveals a high heterogeneity
between the patients. We also examined the data set for
genes that exhibit a different splicing pattern between
two subtypes of NSCLC (AdCa versus SCC).
Methods
Data set and specimens
All investigations were performed in accordance with
the Declaration of Helsinki. After informed consent had
been obtained, biopsies of tumour tissue and of healthy
mucosa from patients with lung cancer undergoing elec-
tive curative surgery from 2001 to 2003 at the Depart-
ment of Surgery, Charité, Campus Benjamin Franklin,
Berlin, Germany, were collected by the clinical partner
with approval by the local ethics committee (reference
number EA4/006/05). Cancer and corresponding epithe-
lial normal tissue specimens were snap frozen in liquid
nitrogen within 20 min following excision and stored
at -80°C. All tissue samples were evaluated by a patholo-
gist before and during macrodissection to ensure an
enrichment of vital tumour cells and normal epithelial
of 80 - 90%. Total RNA preparation was performed with
the RNeasy® kit (Qiagen, Hilden, Germany). In addition,
total RNA isolated from clinical samples was obtained
from Cambridge Biosciences, Ltd. (Cambridge, UK). In
total, 11 paired samples of adenocarcinoma of NSCLC
and NAT (n = 22) and seven paired samples of squa-
mous cell lung carcinoma and NAT (n = 14) were ana-
lysed (for details see additional file 1). All NSCLC
samples have at least 60% tumour content or were
enriched by macrodissection. Concentration of total
RNA was quantified using a NanoDrop spectrometer
and quality of RNA was measured on an Agilent Bioa-
nalyzer (Agilent RNA 6000 Pico and Nano Kit; Agilent
Technologies, Santa Clara, CA, USA). All samples had
an RIN (RNA integrity number) ≥6.9.
Synthesis of fragmented cDNA and microarray
hybridisation
Sample amplification and preparation for microarray
hybridisation was performed according to the Gene-
Chip® whole transcript sense target labelling assay (man-
ual rev. 4, Affymetrix). In brief, in this procedure 2 μg
total RNA of each sample were depleted from rRNA
(RiboMinus™ Transcriptome Isolation Kit (Human/
Mouse), Invitrogen, Carlsbad, CA, USA), reverse tran-
scribed to cDNA, amplified by in vitro transcription,
and reverse transcribed to cDNA. Fragments between
40 and 70 bp were generated enzymatically from 5.5 μg
cDNA, labelled terminally, hybridised onto the Affyme-
trix Human Exon 1.0 ST array, stained and washed, and
finally scanned using an Affymetrix GeneChip® Scanner
3000 7G. Quality of scanned array images was assessed
visually using GeneChip® operating software (GCOS).
The raw data (CEL-files) have been deposited in the
ArrayExpress Archive under accession number
E-MEXP-2644.
Pre-processing and data analysis
In the analysis of the exon array data, we included only
probe sets derived from the core set.T h e s ep r o b es e t s
correspond to exons that are part of well-annotated
transcripts, e.g. RefSeq transcripts [27]. However, in
addition, the exon array contains probe sets that are
backed by less evidence such as EST data and Genscan
predictions, and thus we omitted these probe sets. All
pre-processing operations were conducted in Partek®
Genomics Suite version 6.5 (Partek Inc., St. Louis, MO,
USA). Probe intensities were quantile normalised, a
background adjustment was performed as implemented
in Partek® Genomics Suite using a model based on the
probe sequence, and finally probe intensities were sum-
marised using the RMA algorithm. All probe set intensi-
ties were normalised using quantile normalisation. For
quality assurance and in order to detect outlier samples,
the overall gene expression was analysed by means of a
principal component analysis (PCA) and with hierarchi-
cal clustering based on Pearson’s correlation (average
linkage). Quality assurance with PCA and hierarchical
clustering was also performed using gene level expres-
sion values. To this end, probe set expression values
were summarised to gene level expression values using
Tukey’s biweight algorithm as implemented in Partek®
Genomics Suite.
We omitted all genes containing fewer than 5 probe
sets (leaving 277182 probe sets that correspond to
16613 genes). Analysis of variance (ANOVA) for differ-
ential splicing was performed as implemented in Partek®
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gene, a mixed linear model (MLM) including the factor
pathology group G (tumour or NAT), the random factor
patient P, and the factor exon E was fitted (gene MLM;
equation 1). An ANOVA on the effects alternative spli-
cing (E * G), pathology group (G), and patient (P)p r o -
vides p values for the respective effect. As correction for
multiple testing, the false discovery rate (FDR) was esti-
mated after Benjamini-Hochberg. For each probe set, an
MLM including the factors pathology group G and
patient P w a sf i t t e d( p r o b es e tM L M ;e q u a t i o n2 ) .
Expression ratios were obtained as the contrast of the
pathology group (G)e f f e c tb e t w e e nt u m o u ra n dN A T
from the respective MLM.
IG P E E G S G P =++++ ∗+ ∗ +  ()  (1)
IG P =+++   (2)
where μ is the overall mean of all probe set intensities
I per gene or probe set, respectively, S is a sample-to-
sample random factor nested in pathology group (G)
and patient (P), and ε is the error term. The splicing
index (SI) is defined as
SI =
cg
cg
exon level
gene level
(3)
w h e r ec gi st h ec o n t r a s to ft h ep a t h o l o g yg r o u p( G)
effect between tumour and NAT derived from the
respective MLM.
To discover tumour sub-type dependent differences in
the alternative splicing patterns, the levels of the factors
pathology group G w e r ec h a n g e df r o mt u m o u ra n d
NAT to AdCa, SCC, and NAT. Expression ratios were
obtained as the contrast of the pathology group (G)
effect between tumour and NAT from a MLM ANOVA
based on samples of each subtype, respectively. Likewise,
SI values were calculated for each subtype. Information
about the location of alternative splicing events identi-
fied from well-known transcript variants was obtained
from UCSC genome browser (database hg19, table
knownAlt, table schema described under http://genome.
ucsc.edu/cgi-bin/hgTables?db=hg19&hgta_group=gen-
es&hgta_track=knownAlt&hgta_table=knownAlt&hgta_-
doSchema=describe+table+schema, data available for
download under http://hgdownload.cse.ucsc.edu/golden-
Path/hg19/database/knownAlt.txt.gz).
Background filter
Probe sets with a signal near the background noise are
termed absent. We estimated the expression above
background noise using the MAT algorithm [39] and
utilised the implementation of MAT in ProbeEffects
version 2.0.1. The software was modified in such a way
that detection above background p values are generated
per probe set instead of per gene as in the original
implementation. The MAT background model is fitted
per sample to genomic and anti-genomic background
probes (GC-bins). Probe sets are considered to measure
a signal above the background if p ≤ 0.01. A probe set is
treated as present if p ≤ 0.01 in at least 75% of the sam-
ples of the respective pathology group (tumour or
NAT). Otherwise, a probe set is treated as absent in the
respective sample group. Only probe sets that are absent
in both sample groups, i.e. absent both in tumour as
well as in NAT, are filtered out. Genes containing fewer
than five present probe sets are also removed.
Re-definition of probe sets
New core level probe sets were defined using most
up-to-date transcript data. From publicly available
sources (Ensembl and Vega version 56.37a, RefSeq
release 38), in total 269611 transcript variants related to
42429 gene loci were obtained. Non-redundant exons of
all transcript variants were collected.
Overlapping exons cause splitting of such exons into
distinct probe selection regions (PSRs). In contrast to
the approach followed by Affymetrix, we do not include
less reliable EST data and Genscan predictions for the
generation of PSRs. Thus, we try to avoid extensive frag-
mentation of exons into small PSRs. It can be expected
that PSRs will be larger and that each will be covered by
more probes than in the Affymetrix probe set definition.
Mapping information of exon array probes to the gen-
ome was obtained from X:Map version 56.37a [46].
Probe sets were created for PSRs that are covered by at
least one probe. Probes mapping to multiple locations
on the genome as well as PSRs from repetitive regions
were filtered out (RepBase version 9.11, RM database
version 20050112 [50]). The new probe set definition
together with annotation are available as additional
file 2.
Laboratory validation of exon array results
Of each RNA sample, 50 ng total RNA were reverse
transcribed in cDNA and amplified linearly according to
manufacturer’s instructions (WT-Ovation™ RNA Ampli-
fication System, NuGen Technologies, Inc., San Carlos,
CA, USA). Endpoint reverse transcription PCR (RT-
PCR) was carried out for AdCa/NAT paired samples in
20 μl reactions starting from 100 ng NuGen amplified
template cDNA. Amplification using Immolase™ DNA
polymerase (ImmoMix and ImmoMix Red, Bioline
GmbH, Luckenwalde, Germany) was performed for 30
cycles at 60°C annealing temperature. Assays were
designed to yield two distinct amplicons, one of smaller
size skipping the cassette exon, the larger one including
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purified primers were obtained from TIB MOLBIOL
GmbH (Berlin, Germany). PCR products were separated
by electrophoresis using MetaPhor® Agarose (Lonza,
Basel, Switzerland), cut out of the gel, and extracted
(QIAEX® II Gel Extraction Kit, Qiagen, Hilden, Ger-
many). The extracted products were ligated into a
TOPO® pCR4® vector (TOPO TA Cloning® Kit For
Sequencing, Invitrogen, Carlsbad, CA, USA) and trans-
ferred into chemically competent TOP10 cells. Plasmid
DNA was isolated and sequenced with M13-reverse and
M13(-20)-forward primers at AGOWA GmbH (Berlin,
Germany). Subsequently, the PCR amplicon sequences
were assembled and checked against the transcript
sequences annotated in Ensembl 56.37a.
Transcript variants were quantified using quantitative
reverse transcription PCR (qRT-PCR) in paired samples
of AdCa or SCC and NAT. qRT-PCR assays were
designed using the Universal Probe Library Assay
Design Center (Roche Diagnostics GmbH, Mannheim,
Germany; https://qpcr.probefinder.com/) or the software
Primer3 [51]. HPLC purified primers were obtained
from TIB MolBiol GmbH. Assays were designed either
to yield transcript variant-specific amplicons (transcript
variant expression) or to yield amplicons in exons com-
mon to all known transcripts (gene level expression).
Assay details are given in additional file 4. Where possi-
ble, assays were designed to span an exon-exon junction
such that contaminations of genomic DNA have no
influence. qRT-PCR was carried out in 10 μl reactions
starting from 10 ng NuGen amplified template cDNA.
Amplification was performed with MESA BLUE qPCR
MasterMix Plus for SYBR® Assays (Eurogentec, Seraing,
Belgium). All qRT-PCR reactions were carried out in an
Applied Biosystems ABI Prism® 7900 HT cycler with 40
cycles at 60°C annealing temperature. A dissociation
curve was recorded after the run. All assays were
checked with regard to efficiency and PCR product size
using cDNA from cell lines. After each run, obvious
outliers (no amplification, multiple products) were
manually excluded from the subsequent analysis. Ct
values were set in the logarithmic phase of the PCR-
reaction. Averaging of technical replicates and normali-
sation to the geometric mean [52] of the endogenous
control gene Ct values (ESD, POLR2A [53]) results in
ΔCt values. Both fold-changes (FC) as well as splicing
index (SI) values were calculated from ΔΔCt values (see
equations 5 and 6). Significance was determined by
means of a paired t-test on the SI values.
ΔΔ Δ Δ Ct Ct Ct =− Tumour NAT (4)
FC
Ct :=
− 2
ΔΔ (5)
SI
Ct Ct :
() =
−− 2
ΔΔ ΔΔ transcript variant gene level (6)
We consider exon array results to be validated success-
fully if qRT-PCR results show a significant (paired t-test
p ≤ 0.05) or high (SI ≥ 2.0 or SI ≤ 2.0
-1) difference of tran-
script variant expression that is in agreement with our
hypothesis of AS and the exon array results. Validation is
successful if qRT-PCR results fulfil these criteria for at
least one subtype of NSCLC (AdCa or SCC). In addition,
if an RT-PCR result is available, it must exhibit the AS
pattern in the majority of the samples analysed.
Expression of FOX-genes
Gene expression levels of FOX1 (A2BP1)a n dF O X 2
(RBM9) in different types of cancer and healthy body tis-
sues were obtained from a collection of a total of 1015
samples hybridised on the Affymetrix GeneChip® array
HG-U133_Plus_2.0. Signal intensities were summarised
and normalised with the MAS5.0 algorithm [54]. Mean
values and standard deviations per sample group were
calculated with log-transformed probe set intensities.
Expression of FOX1 and FOX2 transcripts was
detected with RT-PCR as described above. Primer
sequences were: FOX1, forward 5’-CCAGTTGTGGGTG-
CAGTCTA-3’ and reverse 5’-AGCTTCCTTTCTCCCCA-
CAT-3’; FOX2, forward 5’-GCGGACAGTATATGGT
GCAGT-3’ and reverse 5’-GGTTGCAGTAGCAGGCTG
TG-3’. Alternatively spliced exons in RT-PCR products
of FOX2 were identified after cleavage with exon speci-
fic restriction enzymes (FastDigest® Hpy8I, AfeI, and
HinfI; Fermentas, Glen Burnie, MD, USA). DNA frag-
ments obtained from RT-PCR and optionally after diges-
tion with restriction enzymes were separated by agarose
gel electrophoresis as described above or using the Agi-
lent Bioanalyzer (Agilent DNA 1000 Kit; Agilent Tech-
nologies, Santa Clara, CA, USA).
FOX1 gene expression, FOX2 gene expression, and
FOX2 transcript variant expression was quantified using
qRT-PCR as described above. Primers were: FOX1 gene
level, forward 5’-CCTTACCTTCCTGGACTGATTC-3’
and reverse 5’-GTAAGGCTGAGCCATTGTGTC-3’;
FOX2 gene level, forward 5’-TGGAAATTAAGCCCAG-
TAGTTG-3’ and reverse 5’-TGATACCCCCTCTTC
CTGA-3’; FOX2 transcript variants, common forward
primer 5’-GCGGACAGTATATGGTGCAGT-3’;F O X 2
cassette exon, reverse primer 5’-TAGAGGTCAGCACCG-
TAAAATCC-3’; FOX2 exon skipping, reverse junction
primer 5’-CATATCCACCCCTGGATAGG-3’.
Results
We generated an exon array data set from clinical sam-
ples of NSCLC. Our NSCLC data set contains matched
pairs of the AdCa and SCC subtype. Data quality
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tional file 5). In order to identify events of differential
splicing we developed a workflow that essentially con-
sists of three components (Figure 1): (1) filtering of
probe sets whose signals are not significantly above
background signal, (2) re-definition of probe sets
according to most up-to-date transcript annotations
from public databases, and (3) statistical evaluation
using a MLM ANOVA and SI. We have investigated
these three components in comparison to standard
approaches and outline their particular contributions to
a reliable result below.
Background filtering reduces the number of false positive
results
We utilised the generally accepted analysis of variance
(ANOVA) method in order to identify gene loci affected
by differential splicing. A false discovery rate (FDR) of
0.05 corresponds to an ANOVA p value of 0.018 in the
NSCLC data set. According to this analysis, 5340 candi-
date genes are affected by alternative splicing. Of the
genes showing a p value close to zero (p< 1.4 · 10
-45),
we manually inspected the top 100 list with the most
extreme SI, and assigned them to one of six classes
according to their expression profile (Figure 2).
Although this classification has not been verified and
may contain some errors, it will help us to detect key
features of an analysis based on ANOVA and SI alone.
Representative gene profiles are shown in Figure 2. It
became evident that only 30% of all gene loci in the top
100 list are true positives (Figure 2c and 2d). All of the
other candidates appear to be false positives (Figure 2b,
e, and 2f).
In particular, more than half of all gene loci in the top
100 list exhibited probe sets with a low expression value
in both pathology groups (Figure 2e). We assume that
these probe sets are absent in both pathology groups, i.
e. the corresponding exon is expressed neither in
tumour nor in NAT. These probe sets will only measure
t h eb a c k g r o u n ds i g n a li nt h er e s p e c t i v es a m p l eg r o u p
and thus are non-informative. Still, their expression
value affects the statistical analysis: the FC of absent
probe sets does not follow the gene level FC. The statis-
tical ANOVA method scores genes containing such
background level probe sets with a low p value which
leads to the high rate of 57% false positives. Therefore,
w ei n t r o d u c e dad a t as e t - s p e c i f i cbackground filter that
identifies and removes probe sets that are absent in
both sample groups before starting any statistical analy-
sis (see Material and Methods).
After applying our background filter, we repeated the
ANOVA analysis for the identification of candidates dif-
ferentially spliced between NSCLC and NAT (FDR :=
0.05, p = 0.02). This time, we identified 3414 candidate
genes. We compared this result set with the result set
obtained from the analysis without background filter
(5340 candidate genes). There is an overlap of 2505
genes between both sets, i.e. most genes were found
with both analysis methods. First, we inspected the set
of genes that were removed in the analysis with back-
ground filter. Then, we inspected candidate genes that
were found only in the analysis with background filter.
In total 2835 genes were removed by the background
filter. Of these, 1965 genes were completely removed
since less than five of their probe sets were found to be
present. Of the remaining 870 genes, in total 4388
absent probe sets were removed by the background filter
(31% of all core probe sets of these genes). As a conse-
quence, these genes are no longer identified by the
ANOVA method as being differentially spliced. In sum-
mary, the background filter removes 53% of all candi-
date genes from the result list.
However, also 689 additional genes were found to be
differentially spliced only after applying the ANOVA
analysis with background filter. We hypothesise that the
Figure 1 Enhanced workflow for the detection of genes that
are affected by differential splicing. A new definition of core set
probe sets is the basis of the improved workflow. All probe
intensities are summarised to exon expression levels. Estimation of
detection above background noise leads to exon present calls.
Exons that are absent in both sample groups will be removed by
the background filter. In the statistical analysis, only genes with at
least five present probe sets are considered. Both significance as well
as magnitude of differential splicing are derived from an ANOVA
based on a mixed linear model.
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sion is due to the effect of setting a cut-off value (here:
FDR := 0.05). To test this hypothesis, we analysed the
AS ANOVA p values of genes removed by the back-
ground filter and genes that were only found with the
background filter (in total 1559 genes). p values were
taken from the ANOVA analysis both without and with
the background filter. For each gene individually, the
difference of both log-transformed p values was calcu-
lated (Δ log p). Under the assumption that our
background filter has no effect and all differences are
merely an effect of setting a cut-off value, all Δlog p
values should be small and evenly distributed. We
observe a significant skewness in the Δlog p value distri-
bution (skewness of -1.77, D’Agostino skewness test
p< 2.2 · 10
-16). This means that only genes removed by
the background filter show highly different p values.
Apparently, the background filter has the expected effect
and other changes in the result list can be attributed to
setting a cut-off value.
Figure 2 Expression profiles resulting from the exon array can be classified into one of six classes (representative gene profiles are
shown). Classification of the top 100 genes generated using the standard workflow. Red graph: exon expression in NSCLC; blue graph: exon
expression in normal adjacent tissue; green bars: Splicing index per exon (logarithmic scale). (a) A gene that is neither affected by differential
gene expression nor by differential splicing (none of the top 100 genes falls into this category). (b) False-positive result of a differentially
expressed gene caused by exons with very low expression (arrows) outside the linear detection range. (c) Differential splicing (arrow) in the
absence of differential gene expression. (d) Differential splicing (arrows) overlaid by differential gene expression. (e) Exons showing a constantly
low expression value (arrow) that presumably measure the background signal leading to false-positives. (f) Exons showing a constantly high
expression value (arrow) that presumably measure multiple targets leading to false-positives.
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negative rate
Affymetrix provides meta probe set (MPS) files that con-
tain relationships between probe sets and genes. MPS
files are commonly used (e.g. several implementations in
commercial analysis software) to define the set of probe
sets constituting a gene, but this is not intended by
Affymetrix and leads to a loss of many candidates for
differential splicing. We compared this file with suppo-
sedly redundant information from more comprehensive
chip design annotation files. It became evident that a
gene does not contain all available core level probe sets
in the MPS file. Affymetrix provides these annotation
files for the analysis of differential gene expression and
reports that probe sets less suitable for this purpose
were left out. We found that by inappropriate use of the
annotation file in total 220 differentially spliced genes
were lost as false negatives.O u rr e s u l t ss u g g e s tt h a tb y
using the original MPS files for the analysis of differen-
tial splicing, the false negative rate is unnecessarily
increased.
Further analysis improvement by chip re-annotation with
most up-to-date transcript data
As outlined above, it is important to base any analysis of
differential splicing upon a proper definition of probe
sets and gene loci. In contrast to the identification of
novel splice variants, our focus is on finding AS events
that are well-annotated by transcript variants in public
databases and that are differentially expressed in NSCLC
versus NAT. It is intuitive to make use of the best-avail-
able transcript annotations. Thus, we created a new chip
definition based on recent transcript data (Figure 3).
In order to assess the improvements by the new chip
definition, we investigated whether events of differential
splicing can be reliably identified. We chose a straight-
forward approach of manually inspecting gene expres-
sion profiles that were generated on the basis of the
original or the modified chip definition. The impact on
the detection of differential splicing can be most easily
assessed with genes where an AS pattern is not overlaid
by a differential gene expression pattern. Therefore, we
f o c u s e do ng e n e st h a ta r eo n l ya f f e c t e db yd i f f e r e n t i a l
s p l i c i n gb u tt h a td on o te x h i b i td i f f e r e n t i a le x p r e s s i o n
on the gene level (e.g. Figure 2c). A list of genes was
created based on the difference in the absolute SI value:
the top end shows results that were gained and the bot-
tom end shows results that were lost by the new chip
definition. Expression profiles of the top 10 and the bot-
tom 10 candidates were inspected manually.
It became apparent that almost all of the candidates
only identified with the new chip definitions show dif-
ferential splicing for exons not covered by probe sets in
the Affymetrix chip definition. These exons were not
annotated as well-known exons before, but are mean-
while supported by new transcript annotations. In most
cases, the new probe set contains at least two probes, in
one case even nine probes. Thus, additional information
on transcript annotations also leads to additional identi-
fication of differential splicing events. The probe set of
another gene was found to be present in both chip defi-
nitions. Only with the new chip definition does this
probe set indicate differential splicing. Closer investiga-
tion reveals that this probe set contains four probes in
the Affymetrix chip annotation. Three of these probes
map to multiple locations on the genome and thus were
left out in the new chip definition. The new probe set
contains only a single, but more reliable probe that now
indicates differential splicing. On the top 10 list, we
found one case where five genes were combined into a
single transcript cluster according to the new chip defi-
nition. A single RefSeq transcript annotation spans over
five gene loci and thus causes their combination. Differ-
ences in the expression levels of the five genes leads to
extreme SI values. This example demonstrates that an
exon array analysis is sensitive to the definition of tran-
script clusters. Errors in transcript annotations can lead
to artefacts and the example here could represent a false
positive result.
For candidate genes that are no longer identified with
the new chip definition, we found that in most cases
adjacent probe sets were combined to form a single new
probe set. The new probe set measures an averaged sig-
nal which leads to a reduced SI or no evidence for dif-
ferential splicing. In two cases, the evidence for
Figure 3 Workflow for the creation of a new chip definition
(definition of probe sets). Green boxes: Exons and disjunct exon
regions collected from Ensembl 56.37a and RefSeq release 38. Blue:
Probes of the exon array. Red: Dropping of probes caused by non-
unique mapping of probe sequences or repetitive regions.
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tation was provided by probe sets containing a single
probe. In three cases, probe sets of the Affymetrix chip
definition were completely removed. These probe sets
contain either a single probe or overlapping probes and
furthermore, almost all probes map to repeat masked
regions and thus were left out in the new chip defini-
tion. Together, combination of probe sets and removal
of less reliable probes leads to a new chip definition that
is best suited to detect differential splicing of known
exons at the expense of the ability to detect novel
exons. Our improved workflow now consists of a back-
ground filter and a new chip definition which is based
on up-to-date transcript annotations. At the same time,
the number of artefacts due to cross-hybridisation of
probes is reduced.
Application of the new workflow to reliably identify
alternative splicing events
From a previous laboratory validation approach using
candidates from the original workflow (Affymetrix chip
definition, MLM ANOVA p value) we achieved only a
low validation rate. In order to reliably identify genes
that are differentially spliced in NSCLC versus NAT, we
utilised our enhanced workflow (background filter, sum-
marisation using the new chip definition, MLM
ANOVA). Based on all available data, differential spli-
cing candidates were selected by an informed decision-
making approach in order to generate a result list for
laboratory validation. In particular, we inspected known
transcript variants.
Starting with our new chip definition, we omitted all
genes containing fewer than five probe sets (leaving
268132 probe sets that correspond to 16171 genes).
After applying the background filter, we generated a pri-
mary result list based on the AS ANOVA p value (FDR
:= 0.05, p = 0.02). This generated a primary result list of
3096 genes (additional file 6).
Because this list is too large for manual inspection,
sub-lists were generated based on additional criteria.
Sub-list A focuses on genes that are differentially spliced
b u tt h a ta r en o ta f f e c t e db yd i f f e r e n t i a lg e n ee x p r e s s i o n
(see category in Figure 2c). Here, we filtered by pathol-
ogy group p> 0.05 and took the top 100 genes with
most extreme SI (additional file 7). As we know that
most of the alternatively spliced genes are also affected
by differential gene expression (see category in Figure
2d), we generated sub-list B by filtering pathology group
p ≤ 0.05. Only genes showing high homogeneity in all
tumour and all NAT samples (i.e. no dependency on the
patient, patient p> 0.2) were included in this sub-list.
Furthermore, we focused on genes where the gene
expression FC was not higher than the SI. We took the
top 100 genes with most extreme SI (additional file 8).
Thirdly, we generated sub-list C by focusing on probe
sets that are known from transcript annotations (UCSC
genome browser, database hg19, table knownAlt)t ob e
affected by AS. Genes were included in this sub-list if
these specific probe sets had a SI ≤ 1.4
-1 or SI ≥ 1.4 (in
total 194 genes; additional file 9). All expression profiles
of genes in any of these sub-lists (Venn diagram Figure
4; additional file 10) were inspected manually in order
to formulate a hypothesis on the mode of AS (e.g. cas-
sette exon). Based on all available information, 14 pro-
mising candidates were selected for validation by
independent methods in the laboratory.
Laboratory validation of exon array results
Of the 14 candidate genes selected for laboratory valida-
tion, Xi et al. already validated differential splicing of
CEACAM1 in AdCa of NSCLC [34]. For the remaining
13 candidate genes, we hypothesise 10 cassette exon
events, two events of an alternative transcription start
site, one event of intron retention, one event of an alter-
native 5’-splice site, and two events of mutually exclu-
sive exons (in total 16 events of differential splicing, see
Table 1).
Firstly, we tried to validate all of the cassette exon
events, the intron retention event, and the alternative
5’-splice site event using RT-PCR in AdCa samples. In
most cases, we identified two distinct PCR products,
one originating from the short and the other originating
from the long transcript variant of the respective gene
Figure 4 Venn diagram of the final result lists of genes that
are differentially spliced in NSCLC compared to NAT. From the
primary result list of the enhanced workflow (see Figure 1) sub-lists
were generated in order to inspect gene expression profiles
manually. Genes shown were selected for validation using
independent laboratory methods. Sub-list A: Genes that showed
evidence for differential splicing and that were not affected by
differential gene expression (top 100). Sub-list B: Genes that showed
evidence for differential splicing and that were affected by
differential gene expression (top 100). Sub-list C: Genes with exons
that are known to be involved in alternative splicing and where
these exons showed a high splicing index (SI ≤ 1.4
-1 or SI ≥ 1.4).
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Page 10 of 22(see additional file 11). Both the product size as well as
the estimated abundance in tumour versus NAT were in
concordance with the exon array results and with the
AS event hypothesised by us. However, in two events
(CTNND1-CE-3’, intron retention event of KIAA1217)
only two of six patients exhibited the expected result. In
two cassette exon events (CTNND1-CE-5’, MYH14)
m e r e l yas i n g l eP C Rp r o d u c tw as found. Together, this
leads to eight positive and four negative results. In all
cases, sequencing of representative PCR products con-
firmed the expected exon-exon junction sequence
according to our AS hypothesis.
Secondly, we tried to quantify the expression of differ-
ent transcript variants with qRT-PCR. For all of the 16
differential splicing events, transcript variant specific pri-
mers were designed. The SI was calculated separately for
AdCa and for SCC (based on the qRT-PCR results; see
additional file 11). Four events of differential splicing
could not be confirmed in AdCa (ANTXR1, CTNND1-
CE-3’, intron retention event in KIAA1217, MYH14).
The remaining events showed a difference of transcript
variant expression that is in agreement with the exon
array results. High difference (SI ≥ 2.0 or SI ≤ 2.0
-1) was
found for ten events (ADD3, CLSTN1, CTNND1-CE-5’,
FN1, alternative transcription start site in KIAA1217,
MYO18A, NCOR2, NUMB, SYNE2, TPM1-MX-5’)a n d
of these, the results of six events achieved significance
(ADD3, FN1, alternative transcription start site in
KIAA1217, NCOR2, NUMB, TPM1-MX-5’). A smaller
yet significant difference was found in two events (SLK,
TPM1-MX-3’). In total, 12 events of differential splicing
were confirmed in AdCa. In SCC, eight events exhibited
differential splicing that is in agreement with the exon
array results (ADD3, CTNND1-CE-5’, FN1,a l t e r n a t i v e
transcription start site in KIAA1217, NUMB, SLK,
TPM1-MX-5’, TPM1-MX-3’). Although the difference in
transcript variant expression was high in all cases (SI ≥
2.0 or SI ≤ 2.0
-1) the significance level was not reached.
T h r e er e s u l t sa r eb o r d e r l i n e( ANTXR1, CLSTN1,a n d
MYO18A) as there was evidence for differential splicing,
but neither with significance nor with high magnitude.
qRT-PCR results of NCOR2 were inverse compared to
exon array results (details see additional file 12). Four
events of differential splicing were not confirmed with
qRT-PCR in SCC (CTNND1-CE-3’, intron retention
event in KIAA1217, MYH14, SYNE2).
We consider exon array results to be validated if both
RT-PCR and qRT-PCR results are in agreement with
our hypothesis of AS and with the exon array results
(details see Materials and Methods). Based on our vali-
dation criteria, 11 events were validated successfully
whereas five events were devalidated (see Table 1). Of
the latter, two events (CTNND1-CE-3’, intron retention
event of KIAA1217)s h o w e de v i d e n c ef o rd i f f e r e n t i a l
Table 1 Validation results of candidate genes
Laboratory results
Gene Alt. splicing hypothesis RT-PCR Sequencing qRT-PCR AdCa qRT-PCR SCC Status
ADD3 Cassette exon 4/6 + + + validated
ANTXR1 Alt. transcription start site N/A N/A - - devalidated
CLSTN1 Cassette exon 4/6 + + - validated
CTNND1 Cassette exon (5’) - N/A + + devalidated
Cassette exon (3’) 2/6 + - - devalidated
FN1 Cassette exon 5/5 + + + validated
KIAA1217 Alt. transcription start site N/A N/A + + validated
Intron retention 2/6 + - - devalidated
MYH14 Cassette exon - + - - devalidated
MYO18A Cassette exon 4/6 + + - validated
NCOR2 Alternative 5’-splice site 4/6 + + - validated
NUMB Cassette exon 5/6 + + + validated
SLK Cassette exon 5/6 + + + validated
SYNE2 Cassette exon 6/6 + + - validated
TPM1 Mutually exclusive exon (5’) N/A + + + validated
Mutually exclusive exon (3’) N/A + + + validated
A hypothesis of the mode of alternative splicing was formulated based on exon array expression profile and available transcript annotations. Events with
alternative start of transcription were also considered, although they are not alternative splicing events by definition. RT-PCR was conducted using six samples;
shown here is the number of samples that show an alternative splicing pattern that is in concordance with the exon array results. Exon-exon junctions in RT-PCR
products were examined by sequencing. qRT-PCR was performed using transcript variant specific primer pairs for both AdCa and SCC. qRT-PCR results confirmed
the exon array results (+) if they showed a significant (paired t-test p ≤ 0.05) or high (SI ≥ 2.0 or SI ≤ 2.0
-1) difference of transcript variant expression that was in
agreement with the exon array results. Differential splicing of a gene was considered as validated if at least one of the qRT-PCR results was positive. If available,
RT-PCR had to confirm the exon array results in the majority of samples and also sequencing results had to be positive. Detailed result see additional file 11. N/A
indicates that the experiment was not performed.
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tively strict criteria. Likewise, differential splicing of one
cassette exon event of CTNND1 (CTNND1-CE-5’)w a s
confirmed with qRT-PCR but not with RT-PCR and
thus did not meet the validation criteria.
Expression analysis of FOX splicing factors in NSCLC
Interestingly, many of our validated CE events were pre-
viously described as cancer-specific splice variants in
breast and ovarian cancer [55]. It was shown that these
and AS events of other genes depend on the splicing
factor FOX2, which in cancer is either down-regulated
or expressed as an inactive splice variant. We tried to
elucidate whether FOX2 regulates cancer-specific AS
also in other types of cancer such as NSCLC.
First, we analysed expression of the splicing factors
FOX1 and FOX2 using a collection of in total 1015
gene expression microarrays. This database consists of
twelve types of cancer and corresponding normal tissue
as well as 50 other healthy body tissues. FOX1 was only
expressed in brain, heart muscle, and skeletal muscle,
but neither in cancer nor in other healthy tissues (addi-
tional file 13). RT-PCR and qRT-PCR results confirmed
no FOX1 expression in NSCLC and NAT (data not
shown). FOX2 was down-regulated in tumours of endo-
crine origin (thyroid, breast, fallopian tube, ovary, cervix,
and prostate) but up-regulated in kidney, oesophagus,
stomach, and colon cancer. In brain and lung cancer,
the FOX2 expression did not change compared to nor-
mal tissue (Figure 5, additional file 14).
To confirm the expression levels and to investigate AS
of FOX genes in lung cancer, we examined the respec-
tive exon expression profiles in our NSCLC exon array
data set. All probe sets corresponding to exons of FOX1
were found to be absent (data not shown). None of the
FOX2 probe sets showed any indication of differential
expression or differential splicing (Figure 6). The exon
array results confirmed the data from our gene expres-
sion microarray database.
Although no evidence for a change between NSCLC
and NAT was obtained, we wanted to prevent a false
negative result and analysed FOX2 expression using
PCR based methods. For the analysis of AS of FOX2, we
focused on exons in the C-terminal region whose skip-
ping was shown to generate an inactive form of the spli-
cing factor [56]. We noted that two cassette exons are
annotated in this region. In a previous study of the
mouse orthologue of FOX2, yet another cassette exon
designated as M43 was described [57]. An orthologous
open reading frame in the intron sequence of human
FOX2 is also present and we included it as a putative
exon in our analysis. Primers for RT-PCR assays were
placed in the flanking constitutive exons. The experi-
mental results showed that two transcript variants were
present both in NSCLC as well as in normal lung tissue
(Figure 7). The smaller RT-PCR product resembled an
amplicon lacking all cassette exons whereas the longer
product allowed the inclusion of only one of the three
cassette exons. All cassette exons were of similar size,
hence exon-specific restriction enzymes were used in
order to identify the exons involved by cleavage. DNA
fragments after restriction digestion indicated that only
the first of the three cassette exons was expressed. This
was the same exon that had previously been reported as
being skipped in breast cancer [55].
The overall FOX2 expression levels and expression
levels of each of the two transcript variants were quanti-
fied using specific qRT-PCR assays. It became evident
that the longer FOX2 transcript variant, which includes
the first cassette exon, was the dominating form and
was expressed up to six-fold higher than the smaller
transcript variant. But neither the FOX2 gene expression
nor expression of any transcriptv a r i a n td i f f e r e ds i g n i f i -
cantly between NSCLC and NAT (Figure 8).
Quantification of ADD3 transcript variants in NSCLC
One of the successfully validated genes that showed a
significant validation result is now described in more
detail: ADD3. ADD3 contains at least 16 exons of which
exon number 15 (ENSE00000986819) is a known cas-
sette exon of 96 bp. In Ensembl, 22 transcript variants
of ADD3 are annotated (Figure 9a). The exon array
probe set that maps to the cassette exon exhibited a
high SI in the NSCLC exon array data set (Figure 9b-d).
This indicates that the cassette exon is preferably
included in cancer, but skipped in normal tissue. This
differential splicing pattern was detected in 13 of 18
patients (72%). Four patients showed an inverse pattern
and one patient did not exhibit any indication of differ-
ential splicing. There was no correlation between these
differences and factors such as subtype or staging. RT-
PCR of AdCa samples confirmed the differential splicing
pattern measured using the exon array in four cases
(Figure 9e samples 1 - 4). Furthermore, in two patients
(samples 5 and 6) AS clearly took place, but no differ-
ence was observed between tumour and NAT. These
were the same patients that showed an inverse result or
no differential splicing on the exon array. Each tran-
script variant was quantified with qRT-PCR using speci-
fic primer pairs. Moreover, the overall gene expression
of ADD3 was measured using a primer pair targeting a
constitutive gene region. qRT-PCR results (Figure 9f-g)
confirmed that the overall amount of ADD3 did not
change between tumour and NAT; thus, FC and SI
values were similar. Both in AdCa as well as in SCC a
switch from exon skipping to exon inclusion was
observed such that the cassette exon was expressed
more than 2-fold higher in tumour compared to NAT.
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expressed about 2-fold lower in tumour versus NAT;
however, the latter difference was only observed in
AdCa, not in SCC. Based on these results, we postulate
that ADD3 lacking the cassette exon is expressed in nor-
mal lung tissue. In NSCLC, a switch occurs to exon
inclusion while the overall gene expression remains
unchanged.
Alternative splicing patterns that correlate with the
NSCLC sub-type
The laboratory validation results demonstrated that we
could reliably identify genes that are differentially
spliced from an exon array data set using the improved
workflow. Finally, we investigated whether there are
genes whose splicing pattern shows a clear difference
that correlates with the NSCLC subtype, i.e. AdCa and
SCC. Our data set contains a balanced set of AdCa and
SCC samples. In the ANOVA model, the factor subtype
(levels: AdCa, SCC, and NAT) was used instead of fac-
tor pathology (levels: tumour and NAT). In total, 4285
genes showed evidence of differential splicing in at least
one subtype (FDR := 0.05, p = 0.026; additional file 15).
For all samples and subtypes, we calculated separate SI
values. A high difference of SI values between AdCa
and SCC is an indication of a subtype-specific pattern
of AS. There were 16 genes that exhibited a subtype-
specific AS pattern (Δ log2SI ≥ 0.5 or Δ log2SI ≤ -0.5).
In each gene, we analysed the probe set with the high-
est difference in SI values between AdCa versus NAT
compared to SCC versus NAT. With regard to these
probe sets, we found that three genes exhibited a more
pronounced differential splicing pattern in AdCa
(GTPBP10, DUOX1,a n dKIAA1217), whereas 13 genes
had a more pronounced pattern in SCC (e.g. CD44,
FN1). In the case of KIAA1217, the respective probe set
covered the exon that had been quantified using qRT-
PCR. In agreement with the exon array expression
values, also qRT-PCR results showed an increased
expression of the short transcript variant that was more
pronounced in AdCa versus NAT compared to SCC
versus NAT.
Figure 5 Expression of FOX2 in twelve different types of cancer and corresponding normal tissue. Geometric mean signal intensities of
probe set 212104_s_at (Affymetrix expression array HG-U133_Plus_2.0) which measures gene expression of FOX2 (RBM9). FOX2 was down-
regulated in tumour versus normal tissue in strongly hormone-sensitive organs. The numbers of samples per group are shown. Error bars
represent one standard deviation as calculated from log-transformed intensities.
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Despite novel targeted therapies that are available or in
development, treatment of NSCLC remains a major
unmet clinical need. Based on the analysis of individual
genes, it is known that AS occurs and plays an impor-
tant role in cancer. In this study, we present and analyse
a data set of matched pairs of clinical samples of
NSCLC measured with the exon array technology, with
which one can investigate AS genome-wide. We eluci-
date the relatively unexplored field of AS in NSCLC and
analyse selected genes in more detail.
Data set
Clinical samples show high variability. This can be
attributed to patient-to-patient variability and in the
case of cancer, to differences in tumour content and
especially to considerable differences between individual
tumours. We only used matched pairs of NSCLC and
NAT in order to level out patient-to-patient variations.
Tumour content was high in all NSCLC samples and a
sub-set of the samples was enriched by macrodissection.
The data set is balanced such that both major sub-types
of NSCLC (AdCa and SCC) and staging are present in
Figure 6 Details of the exon array results for FOX2 (RBM9). (a) Exon structure and known transcript variants of FOX2 (introns not to scale;
green: Ensembl transcripts; red: RefSeq entries; purple: Genscan predictions). (b) Position of probe sets in the new exon array chip definition
(grey: absent probe sets; blue: present probe sets). (c) Exon expression in the NSCLC data set showed no difference between tumour and
normal adjacent tissue (NAT) (red graph: exon expression in NSCLC; blue graph: exon expression in NAT). (d) Splicing indices for exons in the
NSCLC data set (logarithmic scale).
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tions are available, finding AS patterns specific to each
factor remains a question of power. With 18 sample
pairs our NSCLC data set has the power to discriminate
between tumour and NAT on a level similar to other
cancer data sets with matched samples. While Xi et al.
focused on the AdCa sub-type of NSCLC [34], our data
set also contains the SCC sub-type. This allows identifi-
cation of AS patterns common to both AdCa and SCC.
In addition, one can find sub-type specific AS patterns.
Workflow improvements
It is equally important to use an analysis workflow with
a high detection rate and a justifiable false positive rate.
We found that the standard workflow leads to a low
true positive rate of 30% caused primarily by artefacts.
We introduced an enhanced analysis workflow consist-
ing of (1) filtering of probe sets that are absent in both
of the sample groups, (2) an updated chip annotation,
and (3) a statistical analysis based on a mixed linear
model (MLM) ANOVA and SI.
A modified version of the model-based algorithm
MAT was used in order to identify absent probe sets.
Rather stringent cut-off values were set with regard to
the MAT algorithm p value as well as homogeneity in
one sample group in order to flag a probe set as absent.
Thus, genes with low expression and signal intensities
close to the background noise might have got lost as
false negatives. Nevertheless, these background filter set-
tings resulted in a pronounced decrease of artefacts
w h i c hw ec o n s i d e rt ob ee s s e n t i a lf o rar e l i a b l er e s u l t
list.
We showed that the analysis can be further improved
by an updated chip annotation based on recent tran-
script data. Thus, differential splicing of new exons that
were not annotated as well-known at chip design time
can now be detected. In contrast to the chip definition
created by Affymetrix, we did not include EST data or
predicted exons in order to avoid excessive clustering of
exons. Probes that map to multiple locations to the gen-
o m ea sw e l la sp r o b e sm a p p i n gt or e p e a t - m a s k e d
regions were left out during the reannotation process in
order to avoid artefacts caused by cross-hybridisation.
We found evidence that this approach leads to probe
sets with a higher number of probes and thus a more
reliable measurement of exon expression. Different parts
of an exon that has a predicted internal splice site can
obviously not be discriminated. Our chip definition is
best suited to analyse differential splicing of known tran-
script variants in contrast to the detection of novel tran-
script variants. It should be noted that the new chip
definition can be used in combination with any algo-
rithm of choice and within other analysis workflows
than the one described in this study. All files are compa-
tible with the respective Affymetrix file format and no
changes in software implementations are necessary.
Figure 7 Alternative splicing of FOX2 affecting exons in the C-terminal region. (a) Exon structure (green: constitutive exons; orange:
annotated cassette exons; purple: putative cassette exon predicted by orthology), location of RT-PCR primers (green arrows), and unique
restriction enzyme cleavage sites (exon and primer sizes are shown to scale, introns not to scale). (b) Verification of RT-PCR product sizes
generated from paired samples of adenocarcinoma of NSCLC and NAT of six patients (ø: no template control). (c) RT-PCR product sizes analysed
using the Bioanalyzer. (d) Cleavage by Hpy8I indicated presence of the first cassette exon. (e) No cleavage by AfeI indicated absence of the
second cassette exon. (f) No cleavage by HinfI indicated absence of the third cassette exon.
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Page 15 of 22Thirdly, we introduced an informed decision-making
approach for the identification of genes that are differ-
entially spliced. A MLM ANOVA yielded the signifi-
cance of AS, differential gene expression, and
information about heterogeneity between the patients.
In addition, we estimated the gene level expression
value directly from the MLM by calculating a contrast.
We assume that this is a straight yet robust approach
for reliably calculating the SI. Potential candidate genes
that are affected by differential splicing were identified
using all information available including SI, significance,
known events of alternative splicing, and transcript
annotations. In effect, we used advanced statistical tools
to generate a primary result list. Based on all informa-
tion available, we selected genes from this list and
inspected their exon expression profile manually.
The enhanced workflow was applied to our NSCLC
exon array data set. A validation of the representative
candidates using independent laboratory methods led to
a 69% confirmation rate of exon array data. In addition,
we found genes that are fairly known to be affected by
AS in cancer, e.g. FN1. We did not adjust our workflow
to give better results for well-known cancer genes. That
t h e s ek i n do fg e n e sc a nb ef o u n do nt h er e s u l tl i s tc o n -
firms that enhancements led to a more reliable identifi-
cation of differential splicing in general.
Figure 8 Quantification of FOX2 transcript variant expression. (a) Four of the annotated transcript variants of FOX2 (for complete set, see
Figure 6a) and location of qRT-PCR assays that measure gene level expression and transcript variant expression, respectively. (b) Location of
primers for transcript variant specific qRT-PCR assays in the C-terminal region of FOX2 (green: constitutive exons; orange: cassette exon; grey:
cassette exons not expressed; green arrows: primers; dotted arrow: junction primer). (c) Quantification of gene expression (G) and transcript
variant expression (CE: cassette exon; ES: exon skipping) in adenocarcinoma and squamous cell carcinoma of NSCLC (red bars), respectively,
compared to NAT (blue bars). Bars indicate median ΔCt values, dots represent values for individual samples (AdCa: n = 6; SCC: n = 4), error bars
indicate one standard deviation. (d) Fold-change (FC) of over-expression in adenocarcinoma of NSCLC versus NAT and splicing index (SI). Median
values based on six sample pairs are shown (values for each patient shown as dots), significance was determined using a paired t-test. (e) Fold-
change of over-expression in squamous cell carcinoma of NSCLC versus NAT and splicing index. Median values based on four sample pairs are
shown.
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Page 16 of 22Differential splicing in non-small cell lung cancer
In this study, we found that 330 genes are affected by
differential splicing in NSCLC compared to NAT. We
investigated their expression profiles and moved on to
the next step, the formulation of a hypothesis of AS, i.e.
definition of the exons involved and the mode of AS
(e.g. cassette exon). Of the primary result list, 14 candidate
genes were selected and validated by the independent
laboratory methods RT-PCR and sequencing. In total, vali-
dation results confirmed 11 events of differential splicing
in NSCLC. One of these events represents usage of an
alternative start of transcription which is not strictly a
mode of AS and might be regulated at a different level
than splicing. The other events, however, are genuine
events of AS. Several of the successfully validated genes
have already been shown to be differentially spliced in
Figure 9 Details of the exon array results and the laboratory validation results for ADD3. (a) Exon structure and known transcript variants
of ADD3 (introns not to scale; green: Ensembl transcripts; red: RefSeq entries; purple: Genscan predictions). (b) Position of probe sets in the new
exon array chip definition (grey: absent probe sets; blue: present probe sets). (c) Exon expression in the NSCLC data set suggests higher
inclusion of a cassette exon (arrow) in tumour compared to normal adjacent tissue (NAT) (red graph: exon expression in NSCLC; blue graph:
exon expression in NAT). (d) Splicing indices for exons in the NSCLC data set (logarithmic scale). (e) Verification of RT-PCR product sizes
generated from paired samples of adenocarcinoma of NSCLC and NAT of six patients (ø: no template control). In tumour, exon inclusion was
observed in all cases analysed. Sequencing of representative products confirmed the expected exon-exon junctions (data not shown).
(f) Quantification of gene expression (G) and transcript variant expression (CE: cassette exon; ES: exon skipping) in adenocarcinoma of NSCLC
compared to NAT as measured by qRT-PCR. Median values based on six sample pairs are shown (values for each patient shown as dots), error
bars indicate one standard deviation, significance was determined using a paired t-test. FC: Fold-change of over-expression in adenocarcinoma
of NSCLC versus NAT. SI: Splicing index. (g) Quantification of gene expression and transcript variant expression in squamous cell carcinoma of
NSCLC compared to NAT as measured by qRT-PCR. Median values based on four sample pairs are shown.
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Page 17 of 22cancer. Our data confirmed a switch to the onco-foetal
EDB antigen in FN1. CLSTN1, which is a transmembrane
and cell adhesion protein, was found to be affected by AS
in colon, breast, bladder, and prostate cancer before
[32,58]. Dutertre et al. showed that expression of CLSTN1
transcript variants can be utilised in order to give a prog-
nosis of metastasis-free survival in breast cancer [58]. We
found that exon skipping in CLSTN1, which Dutertre et
al. demonstrated as being associated with metastasis in
breast cancer, occurs in NSCLC. FN1 and CLSTN1 were
also reported in another study as being differentially
spliced in breast and ovarian cancer versus normal tissue
[55]. Closer investigation of the primers used in the RT-
PCR revealed, however, that exons other than the cassette
exons that we found being differentially spliced in NSCLC
were affected. CEACAM1 is a transmembrane protein that
is involved in signal transduction. One alternatively spliced
cassette exon leads to a short isoform. Xi et al. showed
qRT-PCR results indicating that the short isoform of CEA-
CAM1 is over-expressed in both AdCa and SCC of
NSCLC compared to NAT [34]. In our exon array data
set, the signal intensity of the respective probe set was at
the background level and hence no conclusion could be
made. For another cassette exon in CEACAM1, however,
our exon array data set indicated a higher skipping rate in
NSCLC compared to NAT. Tropomyosin 1 (TPM1)c o n -
tains two pairs of mutually exclusive exons. Recent tran-
script annotations in Ensembl 56.37a provide evidence that
t h ef i r s tp a i ri sn o ts t r i c t l ym u t u a l l ye x c l u s i v es i n c eb o t h
exons were found together in two transcript variants.
TPM1 is a tumour suppressor that is involved in cytoskele-
ton remodelling and that has pro-apoptotic properties [59].
With regard to the first exon pair (exon 2 and exon 3), our
results provided evidence for a switch from exon 2 to exon
3 in NSCLC. The exon pair 7A/7B was found to be differ-
entially spliced in different kinds of cancer (colon, bladder,
kidney, lung, prostate, and uterus [60,27,32]). Our results
confirmed that the mutually exclusive exon pair 7A/7B of
TPM1 is differentially spliced in NSCLC such that there is
a switch from exon 7B to exon 7A in tumour. The alterna-
tive 5’-splice site in one exon of NCOR2 leads to different
gene products that are known as SMRT-a (long exon) and
SMRT-τ (short exon) [61]. In this study we demonstrated
that in normal lung tissue both transcript variants of
NCOR2 are equally expressed; however, at least in NSCLC
AdCa a strong shift towards the longer transcript variant
SMRT-a was observed. In KIAA1217, usage of an alterna-
tive start of transcription leads to a shorter transcript that
is in-frame. To our knowledge, cancer-specific usage of an
alternative start of transcription in KIAA1217 has not been
reported before. In the genes ADD3, MYO18A, NUMB,
SLK, and SYNE2, AS events lead to in-frame variations in
the protein sequence affecting from 15 to 48 amino acids.
FOX2 activity is not regulated at the transcript level in
NSCLC
Venables et al. found that many cancer-specific AS
events in breast and ovarian tumours are caused only by
alterations of the splicing factor FOX2 (RMB9)[ 5 5 ] .
Among other genes, this was shown for ADD3,
MYO18A, NUMB, and SYNE2. FOX2-dependent AS was
demonstrated for SLK in a study of human embryonic
stem cells [62]. Thus, many of the cassette exon events
of which we confirmed cancer-specific AS in NSCLC
are known to be regulated by FOX2. This led us to ana-
lyse whether FOX splicing factors (FOX1 or FOX2)
could possibly explain the changes in splicing patterns
between NSCLC and normal lung tissue. FOX1 shows
only limited expression in healthy tissue [63,64] and is
expressed neither in breast nor in ovarian tissue [55].
Our results demonstrated that FOX1 is not expressed in
normal lung tissue or in NSCLC, either. Two distinct
mechanisms were identified by which FOX2 modifies
the splicing pattern of target genes in cancer [55]. In
ovarian cancer, FOX2 expression is significantly down-
regulated compared to normal ovarian tissue. FOX2
itself is also affected by AS in breast cancer and a shift
towards a functionally inactive splice variant was
observed before. Our gene expression microarray data
confirmed that the overall FOX2 expression level is
down-regulated in ovarian cancer compared to normal
ovary. Also other tumours of endocrine origin in our
microarray database showed this kind of down-regula-
tion (thyroid, breast, fallopian tube, cervix, and prostate).
Expression of FOX2 was, however, not changed between
lung cancer and normal lung tissue. Furthermore, other
types of cancer (kidney, oesophagus, stomach, and colon
cancer) showed an even higher expression of FOX2.
Our analysis of splice variants revealed that the func-
tional variant as well as the inactive form of FOX2 is
expressed in lung tissue. A change of the splicing pat-
tern between NSCLC and normal lung tissue was not
observed. This means that there is no shift to the inac-
tive FOX2 transcript variant in NSCLC in contrast to
breast cancer. These findings suggest that FOX2 activity
is not regulated at the transcript level in NSCLC. With
the present data, regulation of FOX2 activity at the pro-
tein level cannot be excluded. Another explanation is
that FOX splicing factors, unlike in other types of can-
cer, are not responsible for the cancer-specific splicing
patterns in NSCLC. FOX2-dependent regulation of AS
might be linked to steroid hormone systems that have a
significant influence on reproductive system tissues like
ovary, cervix, breast, and prostate. This can be explained
for instance by the known interaction of FOX2 protein
with the oestrogen receptor and transcription factor ER
(ESR1) [65].
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Page 18 of 22The long isoform of the cytoskeleton protein ADD3 is
cancer-specific
It was also noted by Venables et al. that many of the
cancer-associated genes found in their study are func-
tionally related to remodelling of the cytoskeleton and
cell movement [55]. Most of the candidate genes of
which we confirmed cancer-specific AS in NSCLC are
also involved in these processes (ADD3, CLSTN1, FN1,
MYO18A, NUMB, SYNE2,a n dTPM1). This is another
indication that AS potentially plays a major role in
tumour progression, especially in tumour invasion and
metastasis. We analysed AS of one gene that is func-
tionally involved in the cytoskeleton in detail.
Gamma-adducin (ADD3) is a structural constituent of
the spectrin-actin cytoskeleton that contains one known
cassette exon. We found that this cassette exon has
higher inclusion in NSCLC compared to NAT for the
majority of patients. Dutertre et al. found that AS of the
same cassette exon is associated with metastasis: they
analysed AS in primary tumours generated from four
different mouse mammary tumour cell lines with differ-
ent potential for metastasis. Cassette exon inclusion in
the mouse ortholog of ADD3 is high only in tumours
originating from cell lines with a high potential for
metastasis [58]. Interestingly, ADD3 was also detected in
acute lymphoblastic leukemia as a fusion protein with
NUP98 [66]. We investigated the gene structure of
ADD3 in more detail in order to examine potential
functional consequences of AS. ADD3 encodes the g
polypeptide chain of adducin. Adducin occurs as a het-
erodimer or heterotetramer of a adducin together with
either b adducin or g adducin. The function of adducin
oligomers in cells is capping (+)-ends of actin filaments
(f-actin) and recruitment of spectrin [67]. All adducin
monomers have a similar structure: a globular head
domain that participates in subunit interaction, a neck
domain, and an unstructured tail domain. At the
C-terminus, a sequence with homology to myristoylated
alanine-rich C kinase substrate (MARCKS) protein can
be found that contains the spectrin/actin interaction site
as well as calmodulin and protein kinase C (PKC) tar-
gets [68]. In ADD3, the cassette exon can generate an
insert of 32 amino acids in the tail domain that is
upstream of the MARCKS-related domain. Protein
structure predictions from Ensembl 56.37a provided
information that this insert leads to a small coiled coil
formation followed by a low complexity region. With
the present data, we cannot estimate what effect the
amino acid sequence insert generated by AS has on
either the oligomerisation of adducin monomers or the
binding of other proteins like f-actin, spectrin, calmodu-
lin, and PKC.
While our exon array analysis and the validation pro-
cess focused on finding events of AS that were present
in the majority of patients in our study, we also found
evidence for considerable heterogeneity, e.g. four of 18
patients showed an inverse AS pattern for ADD3 and an
inconclusive result for NCOR2 in SCC. We gave an out-
look as to how additional factors like tumour subtype
can be considered in our workflow. In total, 16 genes
showed an AS pattern that is differentially pronounced
in AdCa versus SCC. Yet, inclusion of additional factors
is a matter of power and hence study design.
Conclusions
With the NSCLC exon array data set presented here, we
identified and successfully validated genes that exhibit
differential splicing in NSCLC compared to NAT. These
genes are involved in processes like apoptosis, cytoskele-
ton remodelling, and angiogenesis. This underlines the
importance of AS in cancer with regard to key processes
of cancer progression. We showed that the activity of
FOX2, the splicing factor shown to cause cancer-specific
splicing patterns in breast and ovarian cancer, is not
altered in NSCLC at the transcript level. Either cancer-
specific alternative splicing in NSCLC does not depend
on the splicing factor FOX2 or other regulatory mechan-
isms of FOX2 activity, such as at the protein level, are yet
to be discovered. Genes affecting the splicing machinery
or genes up-stream in the signal transduction cascade are
of special interest in the search for novel targeted thera-
peutics. With regard to drug research, it is therefore
desirable to further elucidate the splicing factor network
in NSCLC and other types of cancer.
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